Researchers at the Max Planck Institute for Molecular Biomedicine and the Centro Nacional de Investigaciones Cardiovasculares in Madrid have discovered that blood vessels can adapt when their main growth signalling pathway is blocked. Endothelial cells change their identity to become venous cells, a process called venous genetic reprogramming, allowing them to continue growing independently of the VEGF-VEGFR2 pathway. The finding may explain why anti-cancer drugs targeting the VEGF pathway often lead to resistance and fail, and points to possible combination therapies.
In experiments using a novel genetic mosaic technique, the team led by Rui Benedito showed that mutant cells lacking VEGFR2 signalling could still form blood vessels. Over time, these cells transformed into venous cells. The other receptors, VEGFR1 and VEGFR3, also played a supporting role, helping the cells move and survive when the main pathway was missing. The growth of these reprogrammed vessels even occurred within tumours.
Anti-angiogenic drugs that block VEGF signalling are used with the aim of inhibiting tumour growth and metastasis by blocking blood-vessel growth. However, resistance often develops, and tumours continue to grow. The new research suggests that cells find alternative routes.
'When only one pathway is targeted for long periods of time, vascular cells have time to adapt and find alternative ways of growing. This is natural selection in action, with the fittest cells eventually becoming dominant,' said Benedito.
The identification of alternative venous growth pathways offers new hope that future anti-angiogenesis and anti-cancer therapies could block several pathways at the same time, including VEGF-VEGFR2 and the molecules responsible for venous reprogramming. According to Benedito, 'We expect the combination targeting to be much more effective.'
The technique, developed by Benedito's team, labels mutant and normal cells with different colours, allowing them to be compared directly within the same organism over time. 'We can now very precisely analyze and quantify how mutated cells behave compared to normal cells over long periods of time,' he said.
Explains a long-standing puzzle: why anti-angiogenic cancer drugs lose effectiveness over time.
Reveals a mechanism (venous reprogramming) that may help develop more durable treatments that block multiple pathways.
Could lead to new combination therapies that improve outcomes for cancer patients.
Background
The growth of new blood vessels, angiogenesis, is essential for supplying oxygen and nutrients to tissues. In cancer, tumours can induce angiogenesis to sustain their growth. The vascular endothelial growth factor (VEGF) pathway is central to this process, and many anti-cancer drugs are designed to block it. However, resistance frequently emerges, limiting treatment effectiveness. The new study provides an explanation for this resistance, showing that when the main pathway is blocked, cells can reprogram themselves into venous cells that grow without VEGF signalling.
What to Watch
Further studies on the molecular drivers of venous reprogramming, which could identify specific targets for combination therapy.
Development of drugs that block the alternative venous growth pathways, and clinical trials testing combination approaches.
Whether similar mechanisms exist in other tissues or diseases where angiogenesis is disrupted.
12 claims in this story checked against 1 source: 12 supported.
Show each claim
SupportedBenedito said: “When only one pathway is targeted for long periods of time, vascular cells have time to adapt and find alternative ways of growing. This is natural selection in action, with the fittest cells eventually becoming dominant.”Max Planck Society - Research.: ““When only one pathway is targeted for long periods of time, vascular cells have time to adapt and find alternative ways of growing. This is natural selection in action, with the fittest cells eventually becoming dominant”, says Rui Benedito”
SupportedBenedito said: “We expect the combination targeting to be much more effective.”Max Planck Society - Research.: ““We expect the combination targeting to be much more effective.””
SupportedBenedito said: “We can now very precisely analyze and quantify how mutated cells behave compared to normal cells over long periods of time.”Max Planck Society - Research.: ““We can now very precisely analyze and quantify how mutated cells behave compared to normal cells over long periods of time,” explains Rui Benedito.”
SupportedBlood vessels use venous reprogramming to bypass the main growth pathway.Max Planck Society - Research.: “When this pathway is blocked, vascular cells adapt: They change their identity and become venous cells, which enables them to grow in the absence of VEGF signalling.”
SupportedThe discovery may explain why anti-cancer drugs targeting the VEGF pathway often lead to resistance and fail.Max Planck Society - Research.: “The discovery may explain why anti-cancer drugs targeting the VEGF pathway often lead to resistance and fail—and opens up new avenues for combination therapies targeting the identified venous genetic programmes.”
SupportedResearchers at the Max Planck Institute for Molecular Biomedicine and the Centro Nacional de Investigaciones Cardiovasculares in Madrid made the discovery.Max Planck Society - Research.: “Researchers at the Max Planck Institute for Molecular Biomedicine and the Centro Nacional de Investigaciones Cardiovasculares in Madrid have now demonstrated that when the classic VEGF-VEGFR2 signalling pathway is blocked, endothelial cells [...] adapt”
SupportedMutant cells lacking VEGFR2 signalling could still form blood vessels.Max Planck Society - Research.: “This genetic reprogramming was crucial for the mutant cells’ survival and their ability to form new blood vessels.”
SupportedOver time, the mutant cells transformed into venous cells.Max Planck Society - Research.: “They adapted and “transformed” into venous cells—a process the researchers call “venousization or venous reprogramming.””
SupportedVEGFR1 and VEGFR3 helped the cells move and survive when the main pathway was missing.Max Planck Society - Research.: “In addition, two other receptors—VEGFR1 and VEGFR3—played also a supporting role. They helped the cells move and survive when the main VEGF-VEGFR2 pathway was missing.”
SupportedThe growth of the reprogrammed vessels occurred within tumours.Max Planck Society - Research.: “This process enables vessels without VEGF signalling to grow inside organs and tumors.”
SupportedAnti-angiogenic drugs are used with the aim of inhibiting tumour growth and metastasis by blocking blood-vessel growth.Max Planck Society - Research.: “In cancer research, anti-angiogenic drugs are used with the aim to block blood vessel growth (angiogenesis) in order to inhibit the tumor growth and metastasis.”
SupportedThe genetic mosaic technique labels mutant and normal cells with different colours so they can be compared directly within the same organism over time.Max Planck Society - Research.: “In this approach, both cell types grow side by side, are labeled with different colors, and can be tracked over long periods of time—from embryonic development through adulthood.”